Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 4/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | KISS1R | Q969F8 | 9/20 | 0.56 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.55 |
| ▸ | GLP1R | P43220 | 1/20 | 0.53 |
| ▸ | GCGR | P47871 | 1/20 | 0.53 |
| ▸ | GIPR | P48546 | 1/20 | 0.53 |
| ▸ | GHSR | Q92847 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16508984 | 1.00 | NPBWR1 (0.61) | NPBWR1RXFP1KISS1RIL23RGLP1R | |
| SCHEMBL16509006 | 0.97 | IL23R (0.57) | NPBWR1RXFP1IL23RGHSR | |
| SCHEMBL16509038 | 0.96 | RXFP1 (0.61) | NPBWR1RXFP1IL23RGLP1RGCGR | |
| SCHEMBL16509073 | 0.96 | KISS1R (0.56) | NPBWR1RXFP1KISS1RIL23RGHSR | |
| SCHEMBL16509022 | 0.93 | RXFP1 (0.58) | NPBWR1RXFP1KISS1RIL23RGLP1R | |
| SCHEMBL16509033 | 0.93 | RXFP1 (0.62) | NPBWR1RXFP1IL23RGLP1RGCGR | |
| SCHEMBL16509037 | 0.93 | RXFP1 (0.57) | NPBWR1RXFP1KISS1RIL23RGLP1R | |
| SCHEMBL16509087 | 0.93 | RXFP1 (0.62) | NPBWR1RXFP1IL23RGLP1RGCGR | |
| SCHEMBL16508973 | 0.93 | RXFP1 (0.57) | NPBWR1RXFP1IL23RGLP1RGCGR | |
| SCHEMBL16509063 | 0.93 | GHSR (0.57) | NPBWR1KISS1RIL23RGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301087-A1 | CRF1 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301087-A1 | CRF1 RECEPTOR COMPOUNDS | CRHR1, CRH, CRHR2 | NPBWR1 138/4885RXFP1 161/4885KISS1R 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.